ALYACEN 7/7/7
Clinical safety rating
cautionComprehensive clinical and safety monograph for ALYACEN 7/7/7 (ALYACEN 7/7/7).
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
| Metabolism | Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation. |
| Excretion | Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h. |
| Half-life | Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | 98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity. |
| Bioavailability | Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%. |
| Onset of Action | Oral: 2 hours; Intravenous: 15-30 minutes; peak effect at 4-6 h (oral) or 1-2 h (IV). |
| Duration of Action | 8-12 hours (oral); 6-10 hours (IV). Note: Duration increases in hepatic impairment due to reduced clearance. |
| Molecular Weight | 493.35 Da (trimetrexate glucuronate base) |
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in patients with severe renal impairment (CrCl <30 mL/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (CrCl ≥30 mL/min). |
| Liver impairment | Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A. |
| Pediatric use | Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults. |
| Geriatric use | Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication. |
| 1st trimester | Contraindicated: Risk of malformations (neural tube defects, cleft lip/palate) due to anti-folate effects of trimetrexate. Pregnancy must be excluded before start. |
| 2nd trimester | Contraindicated: Risk of fetal toxicity; consider alternative therapy. |
| 3rd trimester | Contraindicated: May cause fetal harm; avoid use near term due to risk of neonatal toxicity. |
Clinical note
Comprehensive clinical and safety monograph for ALYACEN 7/7/7 (ALYACEN 7/7/7).
| Placental transfer | Extensive; trimetrexate is a folate analog that crosses the placenta and can accumulate in fetal tissues. |
| Breastfeeding | Trimetrexate is excreted in breast milk; due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy and for at least 5 half-lives after last dose. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development. |
| Fetal Monitoring | Monitor blood pressure, glucose, and signs of thromboembolism. In pregnancy, if unintentional exposure, fetal ultrasound to assess for congenital anomalies. No routine monitoring required outside of pregnancy. |
| Fertility Effects | Normal ovulatory function returns after discontinuation. No permanent effects on fertility. Use is contraceptive; no impact on future fertility after cessation. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
| Serious Effects |
Hypersensitivity to trimetrexate or any componentPregnancy (positive pregnancy test before treatment)BreastfeedingSignificant bone marrow suppression (ANC < 1000/mm³, platelets < 75,000/mm³)Pre-existing severe hepatic impairment or cirrhosisPre-existing severe renal impairment (CrCl < 30 mL/min)Concurrent use of folinic acid or folic acid (may reduce efficacy)
| Precautions | Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction), Cerebrovascular disease, Carcinoma of the breast or reproductive organs, Hepatic adenoma or carcinoma, Ocular lesions (retinal thrombosis, papilledema), Gallbladder disease, Carbohydrate/lipid effects, Elevated blood pressure, Hereditary angioedema, Chloasma, Hepatic impairment |
| Food/Dietary | Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended. |
| Clinical Pearls | ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception. |
| Patient Advice | Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo). · If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended. · Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles. · Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache. · This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs). · Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years. |
Loading safety data…